Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistant Enterococcus faecalis isolates
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01050-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Olivia Gladys Funk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA. Hauptthemen laut MEDLINE: Enterococcus faecalis, Cephalosporins, Ampicillin, Anti-Bacterial Agents. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basilea Pharmaceutica International, Ltd., Allschwil, NIH HHS.
Abstract (Originalsprache)
Despite the use of recommended treatments against Enterococcus faecalis infective endocarditis, mortality rates remain at 30%. Penicillin-resistant, ampicillin-susceptible E. faecalis (PRASEF) has been associated with worsened clinical outcomes; however, a more common phenotype, borderline-PRASEF (penicillin minimum inhibitory concentration [MIC] 4–8 µg/mL), decreases the activity of ampicillin-ceftriaxone in vitro . Ceftobiprole presents a promising alternative against borderline-PRASEF and also has shown activity against vancomycin-resistant E. faecalis (VREfs). The ceftobiprole MIC distribution was determined via broth microdilution for 78 E. faecalis clinical blood isolates, including 71 borderline-PRASEF. Ceftobiprole activity alone was compared to ampicillin-ceftriaxone via in vitro 24-hour time-kill assays against 30 E. faecalis isolates, 24 of which were borderline-PRASEF and 15 were VREfs. Ceftobiprole and ceftriaxone were tested at physiologic concentrations ( fCpss 13.9 µg/mL and 17.2 mcg/mL, respectively) and ampicillin at subinhibitory concentrations (0.25 × MIC and 0.5 × MIC). Isolates where ceftobiprole alone had limited activity were tested against ceftobiprole-ampicillin. Ceftobiprole maintained activity against borderline-PRASEF compared to ampicillin-ceftriaxone. Ceftobiprole also demonstrated more activity against VREfs isolates and isolates with an elevated ceftobiprole MIC ≥16 µg/mL, compared to ampicillin-ceftriaxone. Ceftobiprole did not achieve ≥2 log 10 CFU/mL kill in six isolates but was able to achieve this once combined with ampicillin. When tested at ampicillin inhibitory concentrations, ceftobiprole-ampicillin activity trended towards antagonism in two isolates. Overall, ceftobiprole alone had greater activity compared to ampicillin-ceftriaxone, and there may be a potential role of ceftobiprole combination therapy in certain isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA.
ORCID-Profile: Olivia Gladys Funk, Jaclyn A Cusumano
Förderung
- Basilea Pharmaceutica International, Ltd., Allschwil
- NIH HHS
Zitieren
APA
Funk, O. G., Li, J., Khan, I., & Cusumano, J. A. (2026). Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistant Enterococcus faecalis isolates. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01050-25
Vancouver
Funk OG, Li J, Khan I, Cusumano JA. Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistant Enterococcus faecalis isolates. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01050-25
BibTeX
@article{Funk2026,
author = {Funk, Olivia Gladys and Li, Jingyi and Khan, Ifra and Cusumano, Jaclyn A},
title = {Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistant Enterococcus faecalis isolates},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01050-25}
}
EUVIMED